SUPN Q1 2018 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q1 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$90M+57.1% YoY

Gross Profit

$87M96.4% margin

Operating Income

$31M34.7% margin

Net Income

$26M29.1% margin

EPS (Diluted)

$0.49

QoQ Revenue Growth

+2.3%

Cash Flow

Operating Cash Flow

$27M

Free Cash Flow

$27M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$825M

Total Liabilities

$473M

Stockholders' Equity

$352M

Cash & Equivalents

$444M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$90M	$58M	+57.1%
Gross Profit	$87M	$55M	+59.5%
Operating Income	$31M	$17M	+87.0%
Net Income	$26M	$10M	+155.9%

Revenue Segments

Product

$89M50%

Trokendi X R

$71M39%

Oxtellar X R

$19M10%

Royalty

$1M1%